|1.||Humphrey, R: 4 articles (01/2005 - 01/2000)|
|2.||Seymour, L: 3 articles (08/2006 - 09/2003)|
|3.||Tu, D: 2 articles (08/2006 - 09/2003)|
|4.||Hirte, H: 2 articles (08/2006 - 01/2005)|
|5.||Agarwal, V: 2 articles (01/2005 - 03/2001)|
|6.||Williams, Gary M: 1 article (01/2008)|
|7.||Cerven, Daniel R: 1 article (01/2008)|
|8.||Iatropoulos, Michael J: 1 article (01/2008)|
|9.||von Keutz, Eckhard: 1 article (01/2008)|
|10.||de George, George: 1 article (01/2008)|
01/01/2008 - "BAY 12-9566N (BAY), which is a substituted 4-biarylbutyric acid and has the properties of a matrix metalloproteinase (MMP) inhibitor, was tested in the accelerated cancer bioassay (ACB). "
01/01/2003 - "Although all clinical trials in cancer involving BAY 12-9566 have been halted, this MMP inhibitor has never been used in clinical trials in breast cancer. "
03/15/2001 - "We used plasma samples from healthy control subjects and cancer patients enrolled in a dose-finding study for the MMP inhibitor, BAY 12-9566, to assess the activity of MMPs found in plasma and screen for efficacy of the MMP inhibitor. "
03/01/2001 - "We undertook a phase I study of BAY 12-9566, an inhibitor of MMP-2, MMP-9, and MMP-3, in patients with solid tumors to determine its safety, pharmacokinetics, and effects on potential surrogate markers of biologic activity. "
01/01/2000 - "Mean plasma C(ss) values achieved with all dose schedules exceeded BAY 12-9566 concentrations required to inhibit MMPs in vitro and in vascular invasion and tumor proliferation in vivo models. "
|2.||Body Weight (Weight, Body)
12/01/2000 - "Oral treatment of rats for 22 days with 50 mg kg(-1) body weight/d BAY 12-9566 showed decreased AA as determined by improvement in body weight gain (P<0.01), arthritic index (P<0.05) and swelling of paws contralateral to the adjuvant injection site (P<0.05). "
12/01/2000 - "Cartilage destruction was successfully suppressed (P<0.01) in rats treated with either 50 mg kg(-1) body weight/d BAY 12-9566 or 1 mg kg(-1) body weight/d Indomethacin. "
03/01/2003 - "To determine the effect of BAY 12-9566, a matrix metalloproteinase inhibitor, on articular cartilage metabolism in patients with osteoarthritis (OA). "
06/30/1999 - "Long-term trials with BAY 12-9566, a stromelysin inhibitor, have been initiated in osteoarthritis. "
03/01/2001 - "The pharmacokinetic interactions between BAY 12-9566 and two nonsteroidal anti-inflammatory drugs (NSAIDs), naproxen and ibuprofen, were investigated in osteoarthritis (OA) patients. "
03/01/2001 - "Pharmacokinetics, safety, and tolerability of BAY 12-9566 and nonsteroidal anti-inflammatory agents (naproxen, ibuprofen) during coadministration in patients with osteoarthritis."
08/01/2006 - "Patients enrolled in the study had received 6-9 cycles of platinum/paclitaxel containing chemotherapy for stage III or IV ovarian carcinoma, with a response of no evidence of disease, or complete or partial response with residual disease < 2 cm. Patients were then randomized to BAY 12-9566 800 mg p.o. "
01/01/2006 - "Hence, this review covers the summary of the development of anti-angiogenesis as anti-antitumor therapy in pancreatic carcinoma, including matrix-metalloproteinase inhibitors (MMPIs), such as marimastat and BAY 12-9566, anti-VEGF agent, bevacizumab (Avastin, Genentech, South San Francisco, CA, USA), celecoxib (a cyclooxygenase-2 inhibitor), thalidomide and others. "
|5.||Osteosarcoma (Osteogenic Sarcoma)
|3.||Matrix Metalloproteinase 3 (Stromelysin 1)
|5.||Biological Markers (Surrogate Marker)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)